Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology.

Authors

Mohamad Watfa, Kristina Dortche, Gagan Fervaha, Salim K Younis, Abdulrahman Al-Bayati, Betty Wang, Rui M Bernardino, Jesse K McKenney, Samuel Haywood, Ruben Olivares, Riccardo Autorino, Jihad Kaouk, Christopher J Weight, Zeyad R Schwen, Jane K Nguyen

Published in

Prostate cancer and prostatic diseases. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

Grade Group 1 (GG1) prostate cancer is biologically indolent and typically managed with active surveillance (AS), yet pT3a pathology is occasionally identified at radical prostatectomy (RP). Its prognostic significance in GG1 disease remains incompletely defined.
Retrospective cohort of 40 patients with GG1 and pT3a disease on RP (2000-2022), confirmed on central pathologic re-review.
Four patients developed biochemical recurrence (BCR); the cumulative incidence of BCR was 3.2% at 5 years and 10.3% at 15 years. No patient developed metastatic disease or prostate cancer-specific mortality.
GG1 pT3a prostate cancer demonstrates excellent long-term outcomes. Adverse histologic features, not pathological stage alone, drive clinically meaningful risk. Late, stable PSA detectability alone does not signify meaningful recurrence.

PMID:
42469509
Bibliographic data and abstract were imported from PubMed on 18 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.